Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis to $48 after taking a closer look at the company's bottom-line including breaking out non-cash expenses. The analyst projects U.S. Cabometyx sales to grow from $600M in 2018, to $826M in 2019 and $1.07B in 2020. Factoring in a 22% projected tax rate, he forecasts GAAP net income of $300M, or 95c per diluted share, in 2019 to increase to $375M or $1.17, in 2020. Backing out non-cash stock comp and federal taxes, the analyst projects Non-GAAP net income to grow from $431M or $1.37 per diluted share in 2019 to $532M or $1.66 in 2020. Tenthoff reiterates an Overweight rating on Exelixis.